Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis
CNS Drugs · 2026-06 · 40 (6) · 823-833
DOI: 10.1007/s40263-026-01286-9 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift CNS Drugs, online erschienen am 28.03.2026. Verfasst von Chen Jiang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 15261, USA. Hauptthemen laut MEDLINE: Antipsychotic Agents, Aripiprazole, Alzheimer Disease, Olanzapine. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NIA NIH HHS, NIMH NIH HHS, National Institute of Mental Health.
Themen: Demenz
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, University of Pittsburgh School of Pharmacy, Pittsburgh, PA, 15261, USA.
- Department of Psychiatry, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA.
- Lumbrita LLC, Los Gatos, CA, USA.
- Alzheimer Disease Research Center, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
- Department of Biostatistics and Health Data Science, University of Pittsburgh, Pittsburgh, PA, USA.
- Division of Neuropathology, Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA.
ORCID-Profile: Lirong Wang
Förderung
- NIA NIH HHS
- NIMH NIH HHS
- National Institute of Mental Health
- National Institute on Aging
Zitieren
APA
Jiang, C., Krivinko, J., Yu, Z., Sweet, R. A., Zeng, L., Wang, H., Ding, Y., Zeng, Z., Kofler, J., & Wang, L. (2026). Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis. CNS Drugs, 40(6), 823-833. https://doi.org/10.1007/s40263-026-01286-9
Vancouver
Jiang C, Krivinko J, Yu Z, Sweet RA, Zeng L, Wang H, et al. Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis. CNS Drugs. 2026;40(6):823-833. doi:10.1007/s40263-026-01286-9
BibTeX
@article{Jiang2026,
author = {Jiang, Chen and Krivinko, Josh and Yu, Zeshui and Sweet, Robert A and Zeng, Lang and Wang, Hui and Ding, Ying and Zeng, Zheng and Kofler, Julia and Wang, Lirong},
title = {Comparative Mortality Risk of Aripiprazole, Olanzapine, Quetiapine, and Risperidone in Alzheimer’s Disease: A Real‑World Retrospective Cohort Study with Treatment Effect Heterogeneity Analysis},
journal = {CNS Drugs},
year = {2026},
volume = {40},
number = {6},
pages = {823--833},
doi = {10.1007/s40263-026-01286-9}
}
EUVIMED